

Catechol: A Minimal Scaffold for Non-Peptide Peptidomimetics of the $i + 1$ and $i + 2$ Positions of the β -Turn of Somatostatin


Brendan P. Mowery,[†] Vidya Prasad,[†] Craig S. Kenesky,[†] Angie R. Angeles,[†] Laurie L. Taylor,[‡] Jin-Jye Feng,[§] Wen-Long Chen,[§] Atsui Lin,[§] Fong-Chi Cheng,[§] Amos B. Smith, III,^{*,†} and Ralph Hirschmann^{*,†}

Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, MDS Pharma Services, 22011 30th Drive SE, Bothell, Washington 98021, and MDS Pharma Services—Taiwan Ltd., 158 Li-Teh Road, Peitou, Taipei, Taiwan 112, ROC

rjh@sas.upenn.edu

Received June 17, 2006

ABSTRACT



The design, synthesis, and evaluation of a series of catechol-based non-peptide peptidomimetics of the peptide hormone somatostatin have been achieved. These ligands comprise the simplest known non-peptide mimetics of the $i + 1$ and $i + 2$ positions of the somatostatin β -turn. Incorporation of an additional side chain to include the i position of the β -turn induces a selective 9-fold affinity enhancement at the $ss2$ receptor.

Elucidation of the bioactive conformation of somatostatin-14 (**1**, SRIF-14, Figure 1) by Veber and his collaborators at Merck,¹ in conjunction with the earlier results of an alanine scan by Rivier and co-workers,² resulted in the design and synthesis by Veber of both the cyclic hexapeptide L-363,-301 (**2**) and the more potent super agonist MK-678 (**3**).³ The

earlier insightful observation by Walter that there was no definite evidence for the direct interaction of the amide backbone of peptide hormones and neurotransmitters with their receptors,⁴ a proposition that was strongly supported by the report by Freidinger et al. of a potent retro-enantiomer of these peptides,⁵ allowed Hirschmann, Nicolaou, Smith, and co-workers to exploit the β -D-glucoside scaffold⁶ for the attachment of mimics of the three side chains of the β -turn of **1**⁷ that are critical for both binding and receptor

[†] University of Pennsylvania.

[‡] MDS Pharma Services, Bothell, WA.

[§] MDS Pharma Services—Taiwan Ltd., Taipei, Taiwan, ROC.

(1) Veber, D. F.; Holly, F. W.; Paleveda, W. J.; Nutt, R. F.; Bergstrand, S. J.; Torchiana, M.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. *Proc. Natl. Acad. Sci. U.S.A.* **1978**, *75*, 2636.

(2) Vale, W.; Rivier, J.; Ling, N.; Brown, M. *Metab., Clin. Exp.* **1978**, *27*, 1391.

(3) Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J., Jr.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. *Nature* **1981**, *292*, 55.

(4) Walter, R. *Fed. Proc.* **1977**, *36*, 1872.

(5) (a) Freidinger, R. M.; Veber, D. F. *Conformationally Directed Drug Design, Peptides and Nucleic Acids as Templates of Targets*; Vida, J., Gordon, M., Eds.; American Chemical Society: Washington, DC, 1984; p 169. (b) Arison, B. H.; Saperstein, R. In *Peptides: Structure and Function, Proceedings of the 8th American Peptide Symposium*; Hruby, V. J., Rich, D., Eds.; Pierce Chemical Co.: Rockford, IL, 1983; p 349.




Figure 1. Structures of somatostatin (**1**), cyclic hexapeptide agonists **2** and **3**, and the β -D-glucoside peptidomimetic (+)-**4**.

activation, along with the incorporation of a mimic of the second Phe of **2**, which was known to enhance binding.

With these achievements in hand, we recently sought to identify the simplest scaffold that can replace the β -D-glucose ring, while maintaining the side chain topology of a β -turn. We reasoned that a benzene ring might serve this function. As with the β -D-glucose scaffold, we used ether linkages to attach the two most important side chains, an ethylindole to mimic Trp⁸ and an aminopentyl moiety to simulate the Lys⁹ side chain, to arrive at the catechol-derived ligand **5** (Figure 2). Herein, we report that **5** and the subsequently designed catechol-based SRIF ligands **6–8** bind to human somatostatin receptor subtypes 2 and 4 (sst₂ and sst₄). Pleasingly, **5** is among the simplest β -turn mimetics known, comparable in size to the 3-thio-1,2,4-triazole⁸ and imidazopyrazine⁹ derivatives reported recently by Contour-Galcéra et al. and smaller than the tetrahydro- β -carbolines of Poitout and co-workers,¹⁰ Hiroshi's 4,1-benzoxazepin-2-ones,¹¹ and Ellman's 1,4,7-thiadiazonane-3,6-dione scaffolds.¹² This discovery is made

(6) (a) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Salvino, J.; Leahy, E. M.; Sprengeler, P. A.; Furst, G.; Smith, A. B., III; Strader, C. D.; Cascieri, M. A.; Candelore, M. R.; Donaldson, C.; Vale, W.; Maechler, L. *J. Am. Chem. Soc.* **1992**, *114*, 9217. (b) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Leahy, E. M.; Salvino, J.; Arison, B.; Cichy, M. A.; Spoor, P. G.; Shakespeare, W. C.; Sprengeler, P. A.; Hamley, P.; Smith, A. B., III; Reisine, T.; Raynor, K.; Maechler, L.; Donaldson, C.; Vale, W.; Freidinger, R. M.; Cascieri, M. R.; Strader, C. D. *J. Am. Chem. Soc.* **1993**, *115*, 12550.

(7) Brown, M.; Rivier, J.; Vale, W.; Guillemin, R. *Biochem. Biophys. Res. Commun.* **1975**, *65*, 752.

(8) Contour-Galcéra, M.-O.; Sidhu, A.; Plas, P.; Roubert, P. *Bioorg. Med. Chem. Lett.* **2005**, *13*, 3555.

(9) Contour-Galcéra, M.-O.; Poitout, L.; Moinet, C.; Morgan, B.; Gordon, T.; Roubert, P.; Thurieau, C. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 741.

(10) Poitout, L.; Roubert, P.; Contour-Galcéra, M.-O.; Moinet, C.; Lannoy, J.; Pommier, J.; Plas, P.; Bigg, D.; Thurieau, C. *J. Med. Chem.* **2001**, *44*, 2990.

(11) Hiroshi, M.; Suzuki, N.; Miki, T. WO Patent Appl. 98-JP1797, 1998.




Figure 2. MacroModel overlay of **5** (gray) with the NMR solution structure of L-363,301 (green) in H₂O using the Merck Molecular Force Field 94.

even more impressive by the lack of stereogenic centers as in the previous examples.^{8,9}

To assess the viability of the prospective scaffold as a mimetic of the peptide β -turn of SRIF, we initially performed molecular mechanics simulations employing the Merck Molecular Force Field (MMFF94) in aqueous solution and then compared the minimized structures of **5** to the NMR solution structure¹³ of the cyclic hexapeptide L-363,301 (**2**). As illustrated in Figure 2, the tryptophan and lysine residues of **2** overlay well with the indol-3-ylethyl and 5-aminopentyl side chains, respectively, of **5**. A two-carbon linker was chosen to ensure chemical stability of the indole side chain (i.e., to prevent a gramine-type fragmentation).¹⁴

We therefore constructed **5** in four straightforward steps from catechol (see Supporting Information). Biological evaluation revealed that **5** binds the sst₄ receptor with an affinity (K_i) of $2.02 \pm 0.38 \mu\text{M}$, a value similar to that of our original β -D-glucose-based mimetic (+)-**4** ($K_i = 1.65 \pm 0.56 \mu\text{M}$, sst₄).¹⁵

To improve the affinity further, three approaches were explored. First, on the basis of evidence that a fluorinated tryptophan surrogate enhances the affinity of SRIF tetradecapeptide analogues,¹⁶ we proposed incorporation of a fluorine atom at the 5-position of the indole ring to furnish **6**. Second, the observation by Crider et al. of the increased hydrophobicity imparted by chloride substituents¹⁷ suggested the design of the 4,5-dichlorocatechol congener **7**. Third, we

(12) (a) Souers, A. J.; Virgilio, A. A.; Rosenquist, Å.; Fenuik, W.; Ellman, J. A. *J. Am. Chem. Soc.* **1999**, *121*, 1817–1825. (b) Souers, A. J.; Rosenquist, Å.; Jarvie, E. M.; Ladlow, M.; Fenuik, W.; Ellman, J. A. *Bioorg., Med. Chem. Lett.* **2000**, *10*, 2731–2733.

(13) Veber, D. F. In *Peptides—Chemistry and Biology: Proceedings of the 12th American Peptide Symposium*; Smith, J. A., Rivier, J. E., Eds.; ESCOM: Leiden, 1992; p 3.

(14) Snyder, H. R.; Eliel, E. L. *J. Am. Chem. Soc.* **1948**, *70*, 1703.

(15) Prasad, V.; Birzin, E. T.; McVaugh, C. T.; van Rijn, R. D.; Rohrer, S. P.; Chicchi, G.; Underwood, D. J.; Thornton, E. R.; Smith, A. B., III; Hirschmann, R. *J. Med. Chem.* **2003**, *46*, 1858.

(16) Meyers, C. A.; Coy, D. H.; Huang, W. Y.; Schally, A. V.; Redding, T. W. *Biochemistry* **1978**, *17*, 2326.

(17) Crider, A. M.; Liu, S.; Li, T.; Mahajan, A.; Ankersen, M.; Stidsen, C. E. *Letts. Drug Des. Discuss.* **2004**, *1*, 84.

expected that a C-linked benzyl group *ortho* to the Trp-mimicking side chain (**8**) would simulate the affinity-enhancing effect of the Phe⁷ side chain of somatostatin (**1**). Indeed, overlaying the minimized structure of **8** with the NMR structure of L-363,301 reveals good congruency of the side chains (Figure 3). We thus surmised that the addition





Figure 3. Proposed enhancements to the catechol scaffold. Benzylated catechol **8** (gray) was overlaid in MacroModel with L-363,301 (green) as before.

of a benzyl group to the prospective ligand would not interfere with binding.


The syntheses of the prospective 5-fluoroindole ligands **6** and **7** and the benzyl congener **8** are outlined in Schemes 1

Scheme 1. Synthesis of **6** and **7**



and **2**, respectively. For ligands **6** and **7**, commercially available (5-fluoroindol-3-yl)acetic acid (**9**) was converted

Scheme 2. Synthesis of **8**



to the requisite iodide **12** in 71% overall yield over five steps.¹⁸ Alkylation of phenol **13** or the 4,5-dichloro counterpart **14** followed by Staudinger¹⁹ reduction of the azide and alkaline hydrolytic removal of the *tert*-butyl carbamate furnished **6** and **7**.

To acquire prospective ligand **8**, known bromophenol **17**²⁰ was alkylated with 2-[1-*N*-(benzenesulfonyl)indol-3-yl]ethyl iodide to furnish **18** in 83% yield. Treatment of the aryl cuprate derived via lithium–halogen exchange and transmetalation of **18** with benzyl bromide led to **19**, albeit in modest yield.²¹ Removal of the methyl group employing iodotrimethylsilane in dichloromethane at reflux, followed by alkylation of the phenol with 5-azidopentyl iodide, then furnished **20** in 40% yield for the two steps. Completion of the synthesis of **8** was achieved via Staudinger¹⁹ reduction and alkaline hydrolysis.

Binding data for ligands **5**–**8** at the sst₂ and sst₄ receptors are provided in Table 1. The fluorinated congener **6** binds the sst₂ and sst₄ receptors with an affinity similar to that of the parent catechol ligand **5**. A noticeable affinity increase was observed for 4,5-dichlorocatechol **7** at both receptor subtypes due presumably to the increased hydrophobicity of the scaffold in the hydrophobic receptor environment. Of particular note, the benzylated catechol **8**, while showing no discernible improvement in activity at sst₄, displayed a 9-fold affinity enhancement selectively at the sst₂ receptor.

(18) (a) Formation of 5-fluoro-3-(2-hydroxyethyl)indole from 5-fluoroindol-3-ylacetic acid: Mewshaw, R. E.; Zhou, D.; Zhou, P.; Shi, X.; Hornby, G.; Spangler, T.; Scerni, R.; Smith, D.; Schechter, L. E.; Andree, T. H. *J. Med. Chem.* **2004**, *47*, 3823. (b) Silylation of 5-fluorotryptophol: RajanBabu, T. V.; Chenard, B. L.; Petti, M. A. *J. Org. Chem.* **1986**, *51*, 1704.

(19) (a) Staudinger, H.; Meyer, J. *Helv. Chim. Acta* **1919**, *2*, 635. (b) Scriven, E. F. V.; Turnbull, K. *Chem. Rev.* **1988**, *88*, 297. (c) Gololobov, Y. G.; Kasukhin, L. F. *Tetrahedron* **1992**, *48*, 1353.

(20) (a) Bungard, C. J.; Morris, J. C. *Synthesis* **2001**, 741. (b) Ishizaki, M.; Ozaki, K.; Kanematsu, A.; Isoda, T.; Hoshino, O. *J. Org. Chem.* **1993**, *58*, 3877.

(21) (a) Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. *Angew. Chem., Int. Ed.* **2002**, *44*, 1174. (b) Kissau, L.; Stahl, P.; Mazitschek, R.; Giannis, A.; Waldmann, H. *J. Med. Chem.* **2003**, *46*, 2917.

Table 1. Biological Activities of the Catechol-Based Ligands Compared with Those of SRIF and β -D-Glucoside (+)-**4**

ligand	K_i , sst ₂	K_i , sst ₄
SRIF	6.83 \pm 1.54 pM	0.462 \pm 0.132 nM
(+)- 4	4.52 μ M ¹⁵	1.65 \pm 0.56 μ M ¹⁵
5	4.69 \pm 0.37 μ M	2.02 \pm 0.38 μ M
6	3.12 \pm 0.33 μ M	2.08 \pm 0.28 μ M
7	0.749 \pm 0.065 μ M	0.512 \pm 0.120 μ M
8	0.505 \pm 0.031 μ M	1.73 \pm 0.11 μ M

Thus, incorporation of a Phe⁷-mimicking moiety reinforces our contention that the minimal catechol scaffold can mimic a peptide β -turn. With a molecular weight of 338 for the parent ligand (**5**) and of 429 for **8**, these ligands fall well below the often proposed 500 Da upper limit for the optimal molecular weight for drug candidates,²² in contrast to the glucoside ligands, which possess molecular weights of 600 Da or more.

(22) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug Delivery Rev.* **1997**, *23*, 3.

In summary, we have designed, constructed, and evaluated a series of catechol-based ligands, which comprise the simplest known non-peptide mimetics of the $i + 1$ and $i + 2$ positions of the somatostatin β -turn. That the catechol scaffold is sufficiently versatile to permit incorporation of an additional side chain to include the i position of the β -turn (**8**), a modification that induces a selective 9-fold affinity enhancement at the sst₂ receptor, is particularly significant. Efforts toward the synthesis of related congeners are currently underway and will be reported in due course.

Acknowledgment. Financial support was provided by the NIH through Grant GM-41821 and by Merck Research Laboratories through an unrestricted grant. B.P.M. would also like to thank the U.S. Department of Education for a GAANN fellowship and Onur Atasoylu for his assistance in the preparation of this manuscript.

Supporting Information Available: Experimental procedures and spectroscopic data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL061488X